Vitality Watch

Dossier clinicaltrials trial early 16-sep-2026
Small or early-phase human trial or pilot study

A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)

Key claim: The NIBBLE trial will test safety, feasibility, and preliminary efficacy of an 8-week fasting-mimicking diet (three 5-day cycles) or daily 1 mg rapamycin versus placebo in middle-aged APOE ε4 carriers at elevated Alzheimer’s risk.

Abstract

The study aims to evaluate the safety, feasibility, and preliminary efficacy of the fasting-mimicking diet (FMD) or low-dose daily rapamycin treatment relative to a matched placebo control group when administered over 8 weeks in middle-aged adults at elevated risk for Alzheimer’s disease due to the apolipoprotein (APOE) ε4 allele. Participants randomly assigned to the FMD intervention will adhere to FMD for 5-days over three cycles for a period of approximately 8 weeks. Participants randomly assigned to the rapamycin and placebo groups will take 1 mg of rapamycin or a matched placebo pill daily for approximately 8 weeks.

Why this matters

NIBBLE is one of the first RCTs to test two flagship longevity levers — a fasting-mimicking diet and low-dose rapamycin — head-to-head against placebo in a midlife APOE ε4 population, bridging animal geroscience with a clinically enriched Alzheimer’s-risk cohort. As a safety and feasibility trial it will not establish disease or lifespan outcomes, but it sets the design template (and tolerability data) that later efficacy trials in this population will build on.

Source

Link

Briefing card

A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
Stage: trial early · clinicaltrials · 16-sep-2026

If you are a middle-aged APOE ε4 carrier, this is an early-phase trial testing whether 1 mg daily rapamycin or a fasting-mimicking diet is safe and feasible — no efficacy answer yet.

The NIBBLE trial will test safety, feasibility, and preliminary efficacy of an 8-week fasting-mimicking diet (three 5-day cycles) or daily 1 mg rapamycin versus placebo in middle-aged APOE ε4 carriers at elevated Alzheimer's risk.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT06682767

build build 880 · 2bcef25 · 2026-11-18